Duchenne UK’s Project HERCULES awarded prestigious rare disease award

Nov 2, 2018

Written by Juliet Mumby-Croft, Director

Project HERCULES is a unique international multi-stakeholder collaborative project set up by Duchenne UK to develop tools and evidence to support Health Technology Assessment (HTA) and reimbursement decisions for new treatments for Duchenne Muscular Dystrophy (DMD). It brings together eight leading pharmaceutical companies, academics, patient organisations and advisers to develop and build a better evidence base for DMD to aid the pricing and reimbursement stage of drug development. Source Health Economics are developing the core economic model for this collaboration.

This collaboration was recognised by the EURORDIS Black Pearl Company Award for Patient Engagement.


More Insights

HTA monthly – ISPOR 2026

HTA monthly – ISPOR 2026

Written by Paloma Charlesworth Introduction From the 17th–20th May 2026, the Professional Society for Health ...
HTA monthly – April updates

HTA monthly – April updates

Written by Kiera Lander & Oliver Burn 1 - A NICE modular update: adopting the EQ‑5D‑5L UK value set What is ...
HTA quarterly update

HTA quarterly update

Written by Ben Clark, Paloma Charlesworth, and Kiera Lander   This quarterly update highlights recent ...
No results found.